Search bioRxiv⌕ Search

Biology subjects

Plevova, K.

Publications and source records attributed to Plevova, K..

3 recordsLinked to original sources

Retrotransposon Activity in Chronic Lymphocytic Leukemia: Associations with RNA Splicing and TP53 Dysfunction

Retroelements (RE), particularly autonomous Long Interspersed Element-1 (LINE-1), function as potent drivers of genomic instability in various malignancies. While normally silenced by epigenetic mechanisms, their reactivation in cancer cells can drive tumor evolution. TP53 is known to repress LINE-1 transcription; however, the consequences of TP53 dysfunction on retrotransposition and transcriptional activity in chronic lymphocytic leukemia (CLL) remain unknown. To investigate the relationship between TP53 status, LINE-1 retrotranspositional potential, and transcriptomic alterations, we utilized a multi-omics approach, combining a highly sensitive NGS protocol for detecting novel LINE-1 insertions with transcriptomic profiling of transposable elements and protein-coding genes. We applied these methods to a cohort of CLL patients stratified by the presence or absence of TP53 clonal evolution and to CLL-derived cell lines MEC1 and HG3, including CRISPR/Cas9-engineered TP53 mutants. Genomic analysis revealed no evidence of widespread somatic retrotransposition, suggesting that CLL exhibits resistance against de novo LINE-1 insertions. Conversely, transcriptomic profiling uncovered distinct transposon expression signatures aligned with patterns of TP53 mutation status evolution. Notably, differentially expressed genes were significantly enriched in the RNA splicing pathway, indicating that while LINE-1 elements remain largely constrained at the genomic level, their transcriptomic activity may influence cellular rewiring, affecting patterns of TP53 mutation clonal evolution. Based on these results, we argue that the pathogenic contribution of retroelements in CLL lies in transcriptomic dysregulation and splicing alterations, rather than in direct DNA damage caused by LINE-1 insertions.

cancer biology↗

The Minimal Dataset for Cancer of the 1+Million Genomes Initiative

For a real impact on healthcare, precision cancer medicine requires accessibility and interoperability of clinical and genomic data across centres and countries. Due to the heterogeneous digitization in Europe and worldwide, the definition of models for standardised data collection and usability becomes mandatory if countries want to work together on this mission. The European Union 1+Million Genomes (1+MG) initiative, supported by the Horizon 2020 Beyond 1 Million Genomes project, aims at outlining data models, guidance, best practices, and technical infrastructures for transnational access to sequenced genomes, including cancer genomes. Within the framework of the cancer-focused Working Group 9, we developed the 1+MG-Minimal Dataset for Cancer (1+MG-MDC)-a data model encompassing 140 items and organized in eight conceptual domains for the collection of cancer-related clinical information and genomics metadata. The 1+MG-MDC, which results from a multidisciplinary effort, leverages pre-existing models and emphasizes the annotation and traceability of multiple aspects relevant to the complex longitudinal path of the cancer disease and its treatment. We strived to make the 1+MG-MDC easy to adopt, yet comprehensive, addressing the needs of both clinicians and researchers. We will periodically revise and update it to ensure it remains fit for purpose. We propose the 1+MG-MDC as a model to create homogeneous databases, which would, in turn, guide discussions on clinical and genomic features with prognostic or therapeutic value and foster real-world data research.

cancer biology↗

Mobile retroelements induced by hypomethylating agents are restricted to transpose in myeloid malignancies

Retroelements (RE) present in the human genome are silenced via multiple mechanisms, including DNA methylation, to prevent their potentially mutagenic effect. RE activity, demonstrated by their expression and somatic retrotransposition events, is deregulated in multiple tumor types but not in leukemia. We hypothesized that treatment with hypomethylating agents (HMA), commonly used in myelodysplastic syndromes and acute myeloid leukemia, could lead to increased RE activity and somatic retrotranspositions, and contribute to disease progression. We induced expression of ORF1p protein encoded by long interspersed nuclear element-1 (L1) after 72h treatment with HMA in DAMI and HL-60 cell lines. ORF1p was predominantly localized in the cytoplasm, as evidenced by fluorescent microscopy of the DAMI cell line. To study whether long-term HMA therapy may induce somatic retrotranspositions, we (i) treated both cell lines for four weeks, (ii) analyzed a cohort of 17 MDS patients before and on treatment with HMA. Using a previously established sensitive NGS-based method, no RE events were identified. To conclude, we show that although HMA induces the expression of L1-encoded proteins in tumor myeloid cell lines, de novo somatic retrotransposition events do not arise during the long-term treatment of MDS patients and myeloid cell lines with these agents.

cancer biology↗